Subscribe to CDR |
Latest content
| Vol 16 no 51 | |
| CDR RSS feed About RSS |
Adobe Acrobat![]()
This site uses Adobe Acrobat
Download here >
|
Final Issue: Volume 16 Number 51 |
Published on: 21 December 2006 |
Final Issue in PDF |
Last updated: 23 November Volume 16, No.47 (PDF file, 233 KB)
News Archives: | 2006 | 2005 | 2004 | 2003 | 2002 | 2001
CDR Home | News
![]()
The Health Protection Agency has published its annual surveillance report on HIV and other sexually transmitted infections (STIs) in the United Kingdom (UK). The report, entitled A complex picture provides a comprehensive epidemiological picture of the continuing HIV and STI epidemics in the united Kingdom (UK). 2006 marks the 25th anniversary of the first reported case of acquired immunodeficiency syndrome (AIDS) and the beginning of AIDS and HIV surveillance in the UK. This year also marks the roll-out of the National Chlamydia Screening Programme (NCSP) across England, a major sexual health initiative targeting young sexually active people.
Key findings of the report include:
Over the past 25 years, there has been an unprecedented priority given to the control and management of HIV and STIs in the UK. Key initiatives and successes have included: the screening of the blood supply; the early introduction of needle-exchange schemes and harm-minimisation programmes for injecting drug users; confidential and voluntary HIV testing (VCT); population level and targeted health promotion campaigns and interventions; the availability of effective anti-retroviral therapy, and more recently the introduction of antenatal screening for HIV. Nevertheless, HIV and other STIs remain a major public health concern in the UK. In 2005, more than 790,000 diagnoses were made in genitourinary medicine clinics (GUM), and 47,517 individuals seen for HIV related care in the UK.
In 2005 there were 2356 new HIV diagnoses among MSM, the highest on record since the beginning of the epidemic. There is evidence of high rates of ongoing HIV transmission within this group. The annual incidence of HIV infection in MSM attending GUM clinics has remained high at 3.2%. Also in clinic attendees, the prevalence of previously undiagnosed HIV infection in those MSM aged under 25 years, an indicator of relatively recent transmission, was 1.5% for London and 1.3% outside London. There is further evidence of high risk sexual behaviours among MSM in 2005, with increases in cases of gonorrhoea and syphilis (4388 and 1448 respectively).
Diagnoses of HIV infection in people thought to have acquired their infection through heterosexual contact rose from 2031 in 2000 to 4049 reported for 2005. Many of these diagnoses were in black and minority ethnic adults, among whom an estimated 3.7% of black Africans and 0.3% of black Caribbeans were HIV-infected. This correlates respectively to 46 and 3.7 times the estimated prevalence of diagnosed HIV infection in white heterosexuals (0.08%). Among the small proportion of HIV-infected black Africans and black Caribbeans who were born in the UK, over half (59%) had probably acquired their infection within the UK and, where reported, 10% of their partners had also probably been infected within the UK. As the number of BME heterosexuals living with HIV (diagnosed and undiagnosed) in the UK grows, the likelihood increases of expanding heterosexual HIV transmission chains within BME communities living in the UK.
The 1.6% prevalence of HIV among injecting drug users (IDUs) attending specialist drug agencies in England and Wales in 2005 remains low in comparison with other countries. Nevertheless, outside of London prevalence has risen from 0.5% in 2003 to 1.2% in 2005, and the prevalence in London remained elevated at 3.2%. Possible contributing factors to this rise include high rates of direct and indirect sharing of needles, syringes, and related equipment in England (53%), Wales (56%), and Northern Ireland (43%).
There has been continued high uptake of VCT of HIV in the GUM and antenatal settings in 2005. The uptake of VCT among all heterosexuals attending GUM clinics increased to 82% and was sustained at 80% among MSM. One in every 450 women giving birth in England and Scotland in 2005 was HIV-infected and prevalence among women in England living outside London reached 0.13% in 2005. It is estimated that around 95% of HIV-infected pregnant women were diagnosed prior to delivery in 2005, compared with about 83% in 2001.
By the end of the third year of the NCSP, approximately 180 000 opportunistic screens for genital chlamydial infection in under 25 year olds had been undertaken outside of GUM settings. Infection was detected in 10% and 11% of women and men respectively. Almost 95% of index cases were treated, and 80% of these were successfully managed outside of GUM clinic settings.
Treatment and prevention initiatives have been successful not only in maintaining high numbers of HIV-infected individuals on anti-retroviral therapy, but also at reducing the proportion of children exposed to maternal HIV infection, and in delivering hepatitis B vaccine to 90% of eligible MSM attending GUM services. The improvement in access to sexual health services seen in the reduction in waiting times for attendance at GUM clinics is welcome as rapid access to diagnostic and treatment services for HIV and STIs is a key part of infection control. Nevertheless, there is considerable scope for improvement, which includes further increasing access to sexual health services; earlier HIV testing; more focussed prevention programmes for those at high sexual risk; and substantially increasing the volume of chlamydia screening.
A complex picture is accompanied by a series of supplementary data tables, and a slide set, which can be found along with an electronic version of the report at:
<http://www.hpa.org.uk/publications/PublicationDisplay.asp?PublicationID=55>.
Reference
1. UK Collaborative Group for HIV and STI Surveillance. A complex picture. HIV and other sexually transmitted infections in the United Kingdom: 2006. London: Health Protection Agency, 2006. Available at <http://www.hpa.org.uk/publications/PublicationDisplay.asp?PublicationID=55>.
Three cases of pneumococcal pneumonia in young children were detected in a closed-setting in North Tyneside. All three cases, aged between four and five years, attended a reception class at a primary school in Tynemouth. The dates of onset of illness for the cases ranged between 10 and 13 October 2006 and all were hospitalised with acute lobar pneumonia. One case was confirmed with infection due to Streptococcus pneumoniae by blood culture, and subsequently developed empyema, which required surgical drainage. Two cases were blood culture negative, but had clinical features of lobar pneumonia and were positive on urinary antigen for S. pneumoniae infection by Binax® testing. Typing for all three cases (one blood culture and empyema fluid, two serotype-specific antigen detection in urine) detected S. pneumoniae serotype 1.
Serotype 1 is not included in the new 7-valent conjugate pneumococcal vaccine (Prevenar®), and is one of the most invasive pneumococcal serotypes. Serotype 1 is known to be associated with an increased risk of pulmonary complications including empyema [1].
Serotype 1 is rarely detected in carriage studies [2,3]. The epidemiology of the cluster, however, suggested that transmission may have occurred at the school. Action was therefore taken to reduce the risk of further transmission to close contacts. All 64 classroom and 13 household contacts were offered rifampicin chemoprophylaxis. Vaccination (with conjugate or polysaccharide vaccine according to age) was recommended for previously unimmunised contacts belonging to specific at-risk groups as recommended by the CMO (such as asplenics and those who are immunosuppressed) [4].
The action taken was precautionary, and not based on published guidelines An HPA Working Group will be producing guidelines on the management of clusters of invasive pneumococcal disease in the near future.
Outbreaks of pneumococcal disease in children have been described in the literature. There are reports of clusters of pneumococcal pneumonia, bacteraemia and meningitis occurring in child-care facilities [5]. Rifampicin, when used as chemoprophylaxis, may confer a substantial but transient decrease in carriage rates among treated contacts and thus reduce transmission [6]. Polysaccharide vaccination will reduce the risk of invasive disease, particularly in those at higher risk, although it does not reduce carriage (and hence transmission) among contacts.
Transmission of pneumococci is by aerosol, droplets or direct contact with respiratory secretions of someone carrying the organism. Transmission usually requires frequent or prolonged close contact. Recent influenza infection is thought to increase the risk of invasive S. pneumoniae infection [6]. Reports suggest that around 35% of children in this age-group are carriers of S. pneumoniae [3]. Children attending nurseries appear to have higher carriage rates than those who do not [7].
References
1. Tan TQ, Mason EO Jr, Wald ER, Barson WJ, Schutze GE, Bradley JS, et al. Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics 2002; 110:
1-6.
2. Brueggemann AB, Spratt BG. Geographic distribution and clonal diversity of serotype 1 Streptococcus pneumoniae. J Clin Microbiol 2003; 41; 4966-70.
3. Hussain M, Melegaro A, Pebody RG, George R, Edmunds WJ, Talukdar R, et al. A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect 2005; 133: 891-8.
4. Important changes to the childhood immunisation programme. CMO Letter. PLCMO (2006)1. London: Department of Health, 2006. Available at <http://www.dh.gov.uk/PublicationsAndStatistics/LettersAndCirculars/DearColleagueLetters/fs/en>
5. Craig AS, Erwin PC, Schaffner W, Elliott JA, Moore WL, Ussery XT, et al. Carriage of multidrug-resistant Streptococcus pneumoniae and impact of chemoprophylaxis during an outbreak of meningitis at a day care center. Clin Infect Dis 1999; 29:1257-64.
6. Rauch AM, O'Ryan M, Van R, Pickering LK. Invasive disease due to multiply resistant Streptococcus pneumoniae in a Houston, Texas, day-care center. Am J Dis Children 1990; 144:923-7.
7. O’Brien KL, Walters MI, Sellman J, Quinlisk P, Regnery H, Shwartz B, et al. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis 2000;30: 784-9.
The Chief Medical Officer and Chief Nursing Officer have issued a letter summarising best practice on screening for MRSA colonisation and an accompanying screening strategy. Trusts are advised to review their strategies for screening and decolonisation of patients with MRSA carriage immediately. The screening strategy has been devised to help with practical interventions. As a minimum intervention, Trusts are advised to consider models for effective screening of high-risk cohorts, in particular A&E admissions and pre-operative surgical assessment patients.
References
1. CMO/CNO. Screening for MRSA colonisation PL/CMO/2006/4. London: Department of Health, 2006. Available at <http://www.dh.gov.uk/assetRoot/04/14/05/93/04140593.pdf>
2. Screening for Meticillin-resistant Staphylococcus aureus (MRSA) colonisation: a strategy for NHS trusts - a summary of best practice. London: Department of Health, 2006. Available at <http://www.dh.gov.uk/assetRoot/04/14/05/88/04140588.pdf>.